首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy.
【24h】

Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy.

机译:鉴定大鼠前列腺类固醇结合蛋白作为实验性自身免疫性前列腺炎的靶抗原:对前列腺癌治疗的意义。

获取原文
获取原文并翻译 | 示例
           

摘要

The long term goal of this study is to develop autoimmune prostatitis as a therapy for prostate cancer. An immune attack capable of destroying normal prostate epithelial cells should also destroy malignant prostate tissue and provide therapeutic benefit in cancer patients. The current study was initiated to identify antigenic targets for experimental autoimmune prostatitis on the assumption that such proteins might also be suitable targets for immunotherapy of prostate cancer. Male Lewis rats were immunized with syngeneic prostate homogenates, and the immune sera were used to screen prostate proteins for immunoreactivity by Western blot analysis. The dominant protein recognized by the immune sera was purified by ion exchange chromatography and reverse phase HPLC. Microsequence analysis of two polypeptide components of this immunodominant protein demonstrated N-terminal sequences identical with two of the three component chains of rat prostatic steroid-binding protein (PSBP). T cell responses to PSBP were also detected in rats immunized with prostate homogenate. Immunizing male rats with purified PSBP induced vigorous Ab and T cell responses. Significant prostate inflammation was observed in some rats immunized with PSBP. Adoptive transfer of T cells immune to PSBP induced rapid and severe destructive autoimmune prostatitis. These results demonstrate that PSBP is a major target Ag of experimental autoimmune prostatitis in a rat model and may serve as a target Ag for vaccine and T cell therapy against prostate cancer.
机译:这项研究的长期目标是发展自身免疫性前列腺炎作为前列腺癌的治疗方法。能够破坏正常前列腺上皮细胞的免疫攻击也应该破坏恶性前列腺组织并为癌症患者提供治疗益处。假设这些蛋白质也可能是前列腺癌免疫治疗的合适靶点,则开始进行当前研究以鉴定实验性自身免疫性前列腺炎的抗原靶标。用同基因前列腺匀浆免疫雄性Lewis大鼠,并通过Western blot分析将免疫血清用于筛选前列腺蛋白的免疫反应性。通过离子交换色谱和反相HPLC纯化免疫血清识别的优势蛋白。对该免疫优势蛋白的两个多肽成分进行的微序列分析表明,其N端序列与大鼠前列腺类固醇结合蛋白(PSBP)的三个成分链中的两个相同。在用前列腺匀浆免疫的大鼠中也检测到对PSBP的T细胞应答。用纯化的PSBP免疫雄性大鼠会产生强烈的Ab和T细胞反应。在用PSBP免疫的一些大鼠中观察到明显的前列腺炎症。对PSBP免疫的T细胞的过继转移引起快速和严重的破坏性自身免疫性前列腺炎。这些结果证明,PSBP是大鼠模型中实验性自身免疫性前列腺炎的主要靶抗原,并且可以用作针对前列​​腺癌的疫苗和T细胞疗法的靶抗原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号